

North Yorkshire & York Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on the 6th September 2023.

Classification of products:

- G** **Green drug** - Can be initiated and prescribed in all care settings **O**- Second line / alternative green drug.
- ASR** **Amber Specialist Recommendation drug** - Can be recommended by a specialist for initiation in primary care.
- ASI** **Amber Specialist Initiation drug** – Initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.
- ASC** **Amber Shared Care drug** - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care.
- R** **Red drug** - Drugs that should remain under the total responsibility of the specialist. Usually considered as “hospital only” drugs.
- BLACK** **Not Approved** - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within North Yorkshire & York.
- GREY** **Not Reviewed** - Drugs that have not been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in North Yorkshire & York.



Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meeting				
Tirbanibulin (Klisyri@▼, Almirall) 10mg/g ointment	✓ R			Requested for field treatment of non-hyperkeratotic, non hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults. Decision: approved as RED drug to allow dermatology to gain experience of use and to be reviewed in six months. Efudix® remains first line whilst dermatology gain experience with tirbanibulin. Patients should not just be referred to dermatology for consideration of tirbanibulin. Diclofenac (Solaraze®) changed to RED in the treatment pathway for new patients who may require it.
2) New Requests				
None				
3) New formulations & extensions to use				
None				
5) Products considered by NICE				
TA906: Rimegepant for preventing migraine	✓ ASI			The formulary will reflect the TAG – ICB the responsible commissioner.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA908: Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA909: Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer	✓ BLACK			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA910: Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal)				The formulary will reflect the TAG – ICB is the responsible commissioner. Received for information.
TA911: Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
6) Appeals against earlier decisions by the APC				
None				
7) Miscellaneous formulary decisions by the APC				
Agomelatine	✓ ASI			Decision: approved a change to the formulary status of agomelatine with TEWV from RED to AMBER SI to match status across TEWV patch in North East & North Cumbria.

DECISION SUMMARY

Product	Decision			Comments/notes												
	Approved	Refused	Deferred													
Blood glucose meter formulary	✓			<p>The Humber and North Yorkshire MMT in collaboration specialists have reviewed the national recommendations and identified the preferred meters choices in HNY along with corresponding test strips and lancets.</p> <p>Decision:</p> <p>Type 1</p> <table border="1"> <thead> <tr> <th>Patient Cohort</th> <th>Meter Recommendations / price per 50 BG strips</th> </tr> </thead> <tbody> <tr> <td>Suitable for the majority of people that also require a ketone testing meter.</td> <td>Preferred option: GlucoFix Tech GK Other option: GlucoRx HCT</td> </tr> <tr> <td>Require additional functionality as per national recommendations</td> <td>Preferred option: GlucoFix Tech GK Other option: 4SURE Smart Duo</td> </tr> </tbody> </table> <p>Type 2</p> <table border="1"> <tbody> <tr> <td>Suitable for the majority of people with Type 2 diabetes.</td> <td>Preferred option: GlucoFix Tech GK Preferred option (elderly patients): Contour Plus Blue Other option: Finetest Lite</td> </tr> <tr> <td>Require additional functionality as per national recommendations</td> <td>Type 2 diabetes (enhanced functionality) AgaMatrix Agile (when launched) or AgaMatrix – WaveSense JAZZ wireless (until AgaMatrix Agile launched). Type 2 diabetes paediatrics Connect 2 Pharma – On Call Extra Mobile and On Call Extra Voice Type 2 diabetes (Gestational diabetes - GDm-Health™) AgaMatrix – AgaMatrix Agile (when launched) - or AgaMatrix – WaveSense JAZZ wireless</td> </tr> </tbody> </table> <p>Lancets</p> <table border="1"> <tbody> <tr> <td>Lancets which are suitable for the majority of people with Type 1 and 2 diabetes, and those that require additional functionality.</td> <td>Recommended lancets should be less than £3 per 100.</td> </tr> </tbody> </table>	Patient Cohort	Meter Recommendations / price per 50 BG strips	Suitable for the majority of people that also require a ketone testing meter.	Preferred option: GlucoFix Tech GK Other option: GlucoRx HCT	Require additional functionality as per national recommendations	Preferred option: GlucoFix Tech GK Other option: 4SURE Smart Duo	Suitable for the majority of people with Type 2 diabetes.	Preferred option: GlucoFix Tech GK Preferred option (elderly patients): Contour Plus Blue Other option: Finetest Lite	Require additional functionality as per national recommendations	Type 2 diabetes (enhanced functionality) AgaMatrix Agile (when launched) or AgaMatrix – WaveSense JAZZ wireless (until AgaMatrix Agile launched). Type 2 diabetes paediatrics Connect 2 Pharma – On Call Extra Mobile and On Call Extra Voice Type 2 diabetes (Gestational diabetes - GDm-Health™) AgaMatrix – AgaMatrix Agile (when launched) - or AgaMatrix – WaveSense JAZZ wireless	Lancets which are suitable for the majority of people with Type 1 and 2 diabetes, and those that require additional functionality.	Recommended lancets should be less than £3 per 100.
Patient Cohort	Meter Recommendations / price per 50 BG strips															
Suitable for the majority of people that also require a ketone testing meter.	Preferred option: GlucoFix Tech GK Other option: GlucoRx HCT															
Require additional functionality as per national recommendations	Preferred option: GlucoFix Tech GK Other option: 4SURE Smart Duo															
Suitable for the majority of people with Type 2 diabetes.	Preferred option: GlucoFix Tech GK Preferred option (elderly patients): Contour Plus Blue Other option: Finetest Lite															
Require additional functionality as per national recommendations	Type 2 diabetes (enhanced functionality) AgaMatrix Agile (when launched) or AgaMatrix – WaveSense JAZZ wireless (until AgaMatrix Agile launched). Type 2 diabetes paediatrics Connect 2 Pharma – On Call Extra Mobile and On Call Extra Voice Type 2 diabetes (Gestational diabetes - GDm-Health™) AgaMatrix – AgaMatrix Agile (when launched) - or AgaMatrix – WaveSense JAZZ wireless															
Lancets which are suitable for the majority of people with Type 1 and 2 diabetes, and those that require additional functionality.	Recommended lancets should be less than £3 per 100.															

The following documents/guidelines were presented to and approved at the September 2023 meeting of the APC:

- Humber and North Yorkshire Adult Asthma Guideline 2023.
- Humber and North Yorkshire Children and Young People's Asthma Guideline 2023
- NY&Y APC Terms of Reference – updated September 2023.

The following guidelines were presented to and recommended for approval to the HNY IPMOC at the September 2023 meeting of the APC:

- Nil this month.

The following shared care guidelines were presented to and approved at the September 2023 meeting of the APC:

- Nil this month.

The following documents/guidelines were presented to the September 2023 meeting of the APC for comment:

- TEVV Agomelatine prescribing information leaflet.